Related Experiment Video
Updated: Jun 9, 2026

A Rat Model of Middle Cerebral Artery Occlusion/Reperfusion Without Damaging the Anatomical Structure of Cerebral Vessels
Published on: May 17, 2024
Inhibition of TRPC6 degradation suppresses ischemic brain damage in rats
Wanlu Du1, Junbo Huang, Hailan Yao
1Laboratory of Neural Signal Transduction, Institute of Neuroscience, Shanghai Institutes for Biological Sciences, State Key Laboratory of Neuroscience, The Graduate School, Chinese Academy of Sciences, Shanghai, China.
Abstract:
Brain injury after focal cerebral ischemia, the most common cause of stroke, develops from a series of pathological processes, including excitotoxicity, inflammation, and apoptosis. While NMDA receptors have been implicated in excitotoxicity, attempts to prevent ischemic brain damage by blocking NMDA receptors have been disappointing. Disruption of neuroprotective pathways may be another avenue responsible for ischemic damage, and thus preservation of neuronal survival may be important for prevention of ischemic brain injury. Here, we report that suppression of proteolytic degradation of transient receptor potential canonical 6 (TRPC6) prevented ischemic neuronal cell death in a rat model of stroke. The TRPC6 protein level in neurons was greatly reduced in ischemia via NMDA receptor-dependent calpain proteolysis of the N-terminal domain of TRPC6 at Lys¹⁶. This downregulation was specific for TRPC6 and preceded neuronal death. In a rat model of ischemia, activating TRPC6 prevented neuronal death, while blocking TRPC6 increased sensitivity to ischemia. A fusion peptide derived from the calpain cleavage site in TRPC6 inhibited degradation of TRPC6, reduced infarct size, and improved behavioral performance measures via the cAMP response element-binding protein (CREB) signaling pathway. Thus, TRPC6 proteolysis contributed to ischemic neuronal cell death, and suppression of its degradation preserved neuronal survival and prevented ischemic brain damage.
Insights
Suppression of TRPC6 protein degradation prevents brain damage after stroke. This finding offers a new therapeutic strategy for ischemic stroke by preserving neuronal survival and reducing infarct size.
Area of Science:
- Neuroscience
- Cell Biology
- Pathology
Background:
- Focal cerebral ischemia, a common stroke cause, leads to brain injury via excitotoxicity, inflammation, and apoptosis.
- Blocking NMDA receptors has failed to prevent ischemic brain damage, suggesting other pathways are involved.
- Preserving neuronal survival is crucial for preventing ischemic brain injury.
Purpose of the Study:
- To investigate the role of transient receptor potential canonical 6 (TRPC6) in ischemic brain injury.
- To determine if suppressing TRPC6 degradation can prevent neuronal cell death after stroke.
Main Methods:
- Utilized a rat model of focal cerebral ischemia.
- Investigated NMDA receptor-dependent calpain proteolysis of TRPC6.
- Administered a fusion peptide targeting the TRPC6 calpain cleavage site.
- Assessed infarct size and behavioral performance.
Main Results:
- TRPC6 protein levels decreased in ischemic neurons due to NMDA receptor-dependent calpain proteolysis.
- Activating TRPC6 protected against neuronal death, while blocking it increased ischemia sensitivity.
- The fusion peptide inhibited TRPC6 degradation, reduced infarct size, and improved behavior via the CREB pathway.
Conclusions:
- TRPC6 proteolysis contributes to ischemic neuronal cell death.
- Suppressing TRPC6 degradation preserves neuronal survival and prevents ischemic brain damage.
- Targeting TRPC6 degradation represents a potential therapeutic approach for stroke.

